JNJ-37822681

· Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for JNJ-37822681, covering 2014-03-18 to 2014-03-26. Get the full timeline:

Most recent: Clinical Trial Update: An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia [Phase 2]